JPH11509838A5 - - Google Patents

Info

Publication number: JPH11509838A5
Authority: JP; Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

JP1997501683A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11509838A (ja

Filing date

1996-06-05

Publication date

2005-05-12

1996-06-05 Application filed filed Critical

1996-06-05 Priority claimed from PCT/US1996/009342 external-priority patent/WO1996040258A2/en

1999-08-31 Publication of JPH11509838A publication Critical patent/JPH11509838A/ja

2005-05-12 Publication of JPH11509838A5 publication Critical patent/JPH11509838A5/ja

Status Abandoned legal-status Critical Current

Links

JP9501683A 1995-06-07 1996-06-05 充血性心不全症を処置するためのスピロノラクトン化合物とアンギオテンシンｉｉ拮抗物質との組合わせ治療 Abandoned JPH11509838A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48608995A	1995-06-07	1995-06-07
US08/486,089		1995-06-07
PCT/US1996/009342 WO1996040258A2 (en)	1995-06-07	1996-06-05	Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (2)

Publication Number	Publication Date
JPH11509838A JPH11509838A (ja)	1999-08-31
JPH11509838A5 true JPH11509838A5 (2)	2005-05-12

Family

ID=23930539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9501683A Abandoned JPH11509838A (ja)	1995-06-07	1996-06-05	充血性心不全症を処置するためのスピロノラクトン化合物とアンギオテンシンｉｉ拮抗物質との組合わせ治療

Country Status (16)

Country	Link
US (1)	US20040102423A1 (2)
EP (1)	EP0831911B1 (2)
JP (1)	JPH11509838A (2)
KR (1)	KR19990022723A (2)
CN (1)	CN1192696A (2)
AT (1)	ATE216261T1 (2)
AU (1)	AU6158096A (2)
BR (1)	BR9608505A (2)
CA (1)	CA2224222A1 (2)
CZ (1)	CZ291268B6 (2)
DE (1)	DE69620756T2 (2)
DK (1)	DK0831911T3 (2)
ES (1)	ES2175098T3 (2)
IL (1)	IL122246A (2)
PT (1)	PT831911E (2)
WO (1)	WO1996040258A2 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6306826B1 (en)	1997-06-04	2001-10-23	The Regents Of The University Of California	Treatment of heart failure with growth hormone
US6211217B1 (en)	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
DK1216038T3 (da)	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU3408801A (en) *	2000-02-18	2001-08-27	Takeda Chemical Industries Ltd	Tnf-alpha inhibitors
US7482366B2 (en)	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
US7998986B2 (en)	2001-12-21	2011-08-16	Exelixis Patent Company Llc	Modulators of LXR
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
WO2004089296A2 (en)	2003-04-03	2004-10-21	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en)	2004-03-16	2009-04-29	Univ California	REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en)	2004-10-20	2006-04-27	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
US9512125B2 (en) *	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR20150038395A (ko) *	2006-04-04	2015-04-08	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
EP2051696A2 (en) *	2006-08-18	2009-04-29	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
US20110160232A1 (en) *	2007-10-04	2011-06-30	Pingda Ren	Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt)	2008-01-04	2016-02-10	Intellikine Inc	Certas entidades químicas, composições e métodos
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) *	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
MX2011000216A (es) *	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) *	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
AU2009305669A1 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
ES2433225T3 (es)	2009-01-30	2013-12-10	Takeda Pharmaceutical Company Limited	Compuesto con anillos condensados y uso del mismo
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
US8980899B2 (en)	2009-10-16	2015-03-17	The Regents Of The University Of California	Methods of inhibiting Ire1
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3238722B1 (en)	2011-01-10	2019-03-13	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones
CA2821985C (en)	2011-01-11	2019-07-09	Dimerix Bioscience Pty Ltd	Combination therapy
TWI592411B (zh)	2011-02-23	2017-07-21	英特爾立秦有限責任公司	激酶抑制劑之組合及其用途
CN102816126A (zh) *	2011-06-07	2012-12-12	中国药科大学	具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
US9056877B2 (en)	2011-07-19	2015-06-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2734520B1 (en)	2011-07-19	2016-09-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PE20141371A1 (es)	2011-08-29	2014-10-13	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en)	2011-09-02	2013-05-30	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation of ire1
RU2702908C2 (ru)	2012-11-01	2019-10-14	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3964507A1 (en)	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN106456628A (zh)	2014-03-19	2017-02-22	无限药品股份有限公司	用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2016141182A1 (en)	2015-03-03	2016-09-09	Yee Richard W	Compositions and methods for treating ocular diseases
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3474856B1 (en)	2016-06-24	2022-09-14	Infinity Pharmaceuticals, Inc.	Combination therapies
BR112018077075A2 (pt)	2016-06-29	2019-04-30	Universite De Montreal	heterociclos de biarilmetila
AU2019387370A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3257390A (en) *	1963-06-12	1966-06-21	Merck & Co Inc	Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) *	1976-11-16	1985-11-21	Schering AG, 1000 Berlin und 4709 Bergkamen	15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) *	1985-02-18	1986-08-21	Schering AG, 1000 Berlin und 4709 Bergkamen	1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1991012001A1 (en) *	1990-02-13	1991-08-22	Merck & Co., Inc.	Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) *	1990-04-05	1991-10-17	E.I. Du Pont De Nemours And Company	Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) *	1990-10-16	1992-04-17	Karnail Atwal	Dihydropyrimidine derivatives
US5049565A (en) *	1990-12-07	1991-09-17	Merck & Co., Inc.	Microbial transformation process for preparing anti-hypertensive products
EP0586513A1 (en) *	1991-05-10	1994-03-16	Merck & Co. Inc.	Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) *	1992-04-21	1996-06-25	Curators Of The University Of Missouri	Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
AU5449194A (en) *	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) *	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases

1996
- 1996-06-05 AU AU61580/96A patent/AU6158096A/en not_active Abandoned
- 1996-06-05 DE DE69620756T patent/DE69620756T2/de not_active Expired - Fee Related
- 1996-06-05 IL IL12224696A patent/IL122246A/en not_active IP Right Cessation
- 1996-06-05 BR BR9608505A patent/BR9608505A/pt not_active Application Discontinuation
- 1996-06-05 JP JP9501683A patent/JPH11509838A/ja not_active Abandoned
- 1996-06-05 WO PCT/US1996/009342 patent/WO1996040258A2/en not_active Ceased
- 1996-06-05 CZ CZ19973848A patent/CZ291268B6/cs not_active IP Right Cessation
- 1996-06-05 ES ES96919173T patent/ES2175098T3/es not_active Expired - Lifetime
- 1996-06-05 PT PT96919173T patent/PT831911E/pt unknown
- 1996-06-05 EP EP96919173A patent/EP0831911B1/en not_active Expired - Lifetime
- 1996-06-05 AT AT96919173T patent/ATE216261T1/de not_active IP Right Cessation
- 1996-06-05 CN CN96196086A patent/CN1192696A/zh active Pending
- 1996-06-05 KR KR1019970709165A patent/KR19990022723A/ko not_active Ceased
- 1996-06-05 DK DK96919173T patent/DK0831911T3/da active
- 1996-06-05 CA CA002224222A patent/CA2224222A1/en not_active Abandoned
2002
- 2002-10-15 US US10/271,362 patent/US20040102423A1/en not_active Abandoned

Publication	Publication Date	Title
JP2000500228A5 (2)	2004-09-09
JP2000500440A5 (2)	2004-10-21
JP2000500445A5 (2)	2004-10-14
JP2000500033A5 (2)	2004-09-09
JP2000500327A5 (2)	2005-10-06
JP2000500155A5 (2)	2004-10-21
JPH11500289A5 (2)	2004-08-26
JPH11507533A5 (2)	2004-07-29
JP2000500406A5 (2)	2004-10-14
JP2000500361A5 (2)	2004-10-14
JP2000500115A5 (2)	2004-07-08
JP2000500322A5 (2)	2004-09-30
JP2000500258A5 (2)	2004-08-12
JP2000500342A5 (2)	2004-10-21
JP2000500112A5 (2)	2004-10-14
JP2000500166A5 (2)	2004-09-24
JP2000500051A5 (2)	2004-10-14
JP2000500407A5 (2)	2004-10-21
JP2000500397A5 (2)	2004-10-21
JP2000500019A5 (2)	2004-11-04
JPH11511169A5 (2)	2004-09-09
JP2000500346A5 (2)	2005-06-16
JP2000500044A5 (2)	2006-01-05
JPH11515033A5 (2)	2004-07-15
JP2000500257A5 (2)	2004-08-12